{"a":[{"_":"Jazz’s Ziihera secures 2nd survival win to solidify its HER2-positive stomach cancer status","$":{"href":"/pharma/jazz-ziihera-secures-2nd-survival-win-solidify-her2-positive-stomach-cancer-status","hreflang":"en"}}]}

Data ReadoutpositiveZiiheraPositive

AI Analysis

Summary

Jazz Pharmaceuticals' Ziihera achieved a second overall survival win in HER2-positive gastric cancer, strengthening its position as a HER2-targeting agent in this indication.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Second overall survival win in HER2-positive gastric cancer

Importance:7/10

Sentiment:

0.75

oncologygastric cancerbispecific antibodyHER2overall survivalclinical trial

Related Companies

$JAZZ

Read the original article

Published by FiercePharma on August 31, 2026 9:44 AM

Read Original